TITLE

DRAXIS Acquires Canadian Rights to 8 Elan Neurology Products

PUB. DATE
August 1999
SOURCE
Worldwide Biotech;Aug99, Vol. 11 Issue 8, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Draxis Health Inc. has in-licensed from Elan Corp. PLC the exclusive Canadian rights to eight neurology products. Conditions under the agreement; Task of Draxis Pharmaceutica; Comments from officials of both companies.
ACCESSION #
2110823

 

Related Articles

  • Product Summaries.  // Worldwide Biotech;Aug99, Vol. 11 Issue 8, p3 

    Presents information on the neurology products being marketed by Draxis Health Inc. in Canada. Mechanism of action of Zanaflex; Diastat; Mysoline.

  • Elan Digs Out from Under. Houlton, Sarah // Pharmaceutical Executive;Dec2002, Vol. 22 Issue 12, p22 

    Assesses the decline of 2002 third quarter earnings of pharmaceutical company, Elan Corp. in the U.S. Licensing agreement between Elan Corp. and Watson Pharmaceuticals Inc. on the marketing of nifedipine; Generic competition of Zanaflex; Decline of investments in the biotechnology companies.

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/23/2007, Vol. 18 Issue 164, p2 

    This section offers news briefs on the pharmaceutical industry. Alfacell Corp. reported that Onconase decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. Biogen Idec Inc. and Elan Corp. Plc reported that the National Institute for Health and Clinical...

  • Curis and Elan conclude neurology joint venture.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p12 

    Focuses on the terms of the agreement signed between Curis Inc. and Elan Corp. in the U.S. Development of small molecule drugs; Treatment of the patients with nervous system disorders; Increase on the number of distributors.

  • OTHER NEWS TO NOTE.  // BioWorld International;12/16/2009, Vol. 14 Issue 50, p2 

    This section offers news briefs related to biotechnology. Diurnal Ltd. has raised 300,000 British pounds with a further 300,000 British pounds invested by Finance Wales which will allow it to complete Phase I trials of its hydrocortisone. The Japanese Ministry of Health, Labor and Welfare has...

  • Elan: realigning its CNS franchise.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p4 

    Reports that Elan Corp. PLC has sold its rights to Zonegran and Frova drugs to Eisai Co. Ltd. and Vernalis Group Inc. in Ireland. Impact of the drugs' sale on improving its profitability; Amount expected by the company to be generated by its novel immunosuppressant drugs; Concentration of Elan...

  • Generics Watch.  // Drug Store News;12/13/99, Vol. 21 Issue 20, p54 

    Presents articles pertaining to generics in the United States. Decision of the Senate Judiciary Committee in postponing consideration of the `Drug Patent Term Restoration Review Procedure Act'; Licensing agreement between Schein Pharmaceutical and Elan Corp. PLC; Move of the Food and Drug...

  • Current Treatment Approaches for Neoplastic Meningitis: Nursing Management of Patients Receiving Intrathecal DepoCyt{supTM]. Craig, Catherine // Oncology Nursing Forum;Sep2000, Vol. 27 Issue 8, p1225 

    Discusses neoplastic meningitis and the nursing implications for the intrathecal administration of chemotherapy. Signs and symptoms of neoplastic meningitis; Diagnosis; Treatment.

  • Opinion and Evidence in Neurology and Psychiatry.  // CNS Drugs;2003, Vol. 17 Issue 7, p533 

    The management of neurological and psychiatric disorders is a vast and evolving area for researchers, primary care physicians and specialists. To help you keep up to date with the latest advances worldwide on all aspects of drug therapy for neurological and psychiatric disorders, this section of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics